EVT 302: MAO-B inhibitor

EVT 302 MAO-B inhibitor: Orally active, potent, highly selective and reversible inhibitor of MAO-B

• In development for smoking cessation; potential for disease modification in Alzheimer's disease.
• High degree of selectivity will allow dosing of EVT 302 to achieve complete inhibition of MAO-B without the liability associated with MAO-A inhibition.

First Phase II study in smoking cessation underway

MAO-B inhibition in smoker's brain

Evotec has successfully completed a Phase I safety and tolerability trial with 4 weeks dosing of EVT 302. In addition, single and repeat dose PET studies have been conducted to study brain MAO-B inhibition with EVT 302 to assist dose selection for Phase II.

Evotec commenced the first Phase II study of EVT 302 in Feb 2008 which is designed to investigate the influence of EVT 302 on craving and withdrawal symptoms after short-term deprivation of cigarettes. A second Phase II study in smoking cessation commenced in H2 of 2008.

For the latest press release announcing the start of Phase II clinical trials for EVT 302 (11 Sep 2008) click here

Previous Press Releases on EVT 302

28 Feb 2008

Evotec Starts Phase II in Smoking Cessation with EVT 302

07 Jan 2008

Phase I Safety and Tolerability Study with EVT 302 Successfully Completed

22 Mar 2007

Evotec Initiates its First Phase I Clinical Study with EVT 302